Demographics of the 15 patient cohort consists of 10 (66.7%) with DH-DLBCL and 5 others with MYC+ NHL, 9 (60%) with ≥ 3 prior therapies, 4 (26.7%) refractory to last treatment, 6 (40%) with bulky disease > 7.5 cm, and 10 (66.7%) Ann Arbor staging at study entry stage IV (Supplementary Table S4). Here, MYC is linked to non-Hodgkin lymphoma.